Protein misfolding: understanding biology to classify and treat synucleinopathies
Open Access
- 11 February 2025
- journal article
- review article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 132 (11) , 1645-1654
Abstract
Protein misfolding and aggregation is a major pathological hallmark in a variety of human conditions, including cancer, diabetes, and neurodegeneration. However, we still do not fully understand the role of protein accumulation in disease. Interestingly, recent breakthroughs in artificial intelligence (AI) are having a tremendous impact on our ability to predict three-dimensional protein structures and understand the molecular rules governing protein folding/misfolding. This progress will enable us to understand how intrinsic and extrinsic factors trigger protein misfolding, thereby changing protein function. These changes, in some cases, are related to normal biological responses and, in other cases, associated with pathological alterations, such as those found in many neurodegenerative disorders. Here, we provide a brief historical perspective of how findings in the field of prion diseases and prion biology have enabled tremendous advances that are now forming the basis for our understanding of disease processes and discuss how this knowledge is now emerging as central for our ability to classify, diagnose, and treat devastating neurodegenerative disorders such as Parkinson’s and Alzheimer’s diseases.Keywords
Funding Information
- Herzzentrum Göttingen
This publication has 66 references indexed in Scilit:
- Initial biological classification of Lewy body diseases: No consensus on terminologyAlzheimer's & Dementia, 2024
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Disentangling and quantifying the relative cognitive impact of concurrent mixed neurodegenerative pathologiesActa Neuropathologica, 2024
- Investigating alpha‐synuclein co‐pathology in Alzheimer's disease by means of cerebrospinal fluid alpha‐synuclein seed amplification assayAlzheimer's & Dementia, 2024
- Functional Amyloids: The Biomaterials of Tomorrow?Advanced Materials, 2024
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current ConceptsMovement Disorders, 2022
- Salivary α‐Synuclein RT‐QuIC Correlates with Disease Severity in de novo Parkinson's DiseaseMovement Disorders, 2022
- Interactions of pathological proteins in neurodegenerative diseasesActa Neuropathologica, 2017
- The sour side of neurodegenerative disorders: the effects of protein glycationThe Journal of Pathology, 2010